A Phase 1 interventional study of Eplerenone and Microcrystalline Cellulose NF (placebo) in Intraocular Pressure (IOP) and Healthy Adult, sponsored by University of Florida. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by University of Florida · Phase 1, Interventional, and Basic science
Among 300 studies in Ocular Hypertension with a site in United States — 28 open to participants now, 35 under way, 6 of them phase 3. Ocular Hypertension · United States.
Among the 300 studies in Ocular Hypertension with a site in United States, this one is the 212th largest by planned enrollment of the 259 interventional ones that give a count, is one of 15 that started in 2026, is one of 19 in phase 1, reaches primary completion later than 17 of the 34 other live ones, and was the 298th registered.
659 studies on the registry are indexed under Ocular Hypertension; 48 are open to participants now.
Browse Ocular Hypertension studies →28 of the 300 studies in Ocular Hypertension with a site in United States are open now. Recruiting first, the newest first:
Tavo Biotherapeutics · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18+
YS Life Science Co., Ltd. · Sites in United States, India
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Ocular Hypertension studies recruiting now, 31 (86%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
300 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 110 · Phase 3 72 · Phase 4 36
First in 1976; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 114 across 520 interventional studies indexed under Ocular Hypertension.
Median enrollment 106 across the 259 interventional studies, 88 across the 28 observational. Of the 246 that completed or were terminated, 112 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
230 of 300 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,288 studies on the registry; 200 are open to participants now.
Of its 180 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 1 study filed under Ocular Hypertension — fewer than ten, so there is no comparison to draw.
13 of the studies in Ocular Hypertension with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04967989Phase 3University of PittsburghClarifying the Optimal Application of SLT Therapy Trial | 2027-06-30 |
| NCT07661329Phase 3YS Life Science Co., Ltd.A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | 2027-11-01 |
| NCT06964191PolyActiva Pty LtdEvaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension | 2026-11-15 |
| NCT06615661Iantrek, Inc.A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma | 2026-12 |
| NCT07298356Duke UniversityAutomated Applanation Tonometry - Updated | 2026-12-29 |
Add all 13 to your calendar (.ics) → With an account.
Among the 300 studies in Ocular Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine whether eplerenone lowers eye pressure in healthy adults. Eplerenone is a medication approved by the U.S. Food and Drug Administration for other medical conditions. Researchers will compare eplerenone with placebo (a substance containing no active drug) to determine whether eplerenone affects intraocular pressure (IOP). Participants will receive both eplerenone and placebo during different study periods and will have their eye pressure measured throughout the study. Blood pressure, kidney function, and potassium levels will also be monitored for safety.
This randomized, placebo-controlled crossover study will evaluate the effect of eplerenone on intraocular pressure (IOP) in healthy adults. Eplerenone is a selective mineralocorticoid receptor antagonist approved for other medical conditions.
Participants will receive eplerenone and placebo during separate study periods according to the study protocol. IOP will be measured at specified study visits to evaluate changes associated with eplerenone compared with placebo. Safety monitoring will include assessment of blood pressure, kidney function, and serum potassium levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive oral eplerenone 50 mg once daily for one week, followed by a two-week washout period, and then matching placebo once daily for one week.
Drug: Eplerenone · Drug: Microcrystalline Cellulose NF (placebo)
Participants receive matching placebo once daily for one week, followed by a two-week washout period, and then oral eplerenone 50 mg once daily for one week.
Drug: Eplerenone · Drug: Microcrystalline Cellulose NF (placebo)
Eplerenone 50 mg administered orally once daily for one week. In this randomized, double-masked crossover study, participants receive eplerenone during one treatment period and matching placebo during the other treatment period, with a two-week washout period between treatments.
Matching placebo capsule containing Microcrystalline Cellulose NF, administered orally once daily for one week. The placebo is prepared by the Investigational Drug Service to match the study intervention for use in the double-masked crossover design.
Change in Mean Intraocular Pressure With Eplerenone Compared With Placebo
Mean intraocular pressure (IOP) will be calculated from Goldmann applanation tonometry measurements obtained at approximately 9:00 AM, 12:00 PM, and 3:00 PM at the end of each treatment period. The primary analysis will compare the within-subject difference in mean IOP during eplerenone treatment versus placebo treatment.
Time frame: End of each 1-week treatment period (Day 7 and Day 28)
Plan to share: Undecided — The study team has not yet determined whether individual participant data will be shared with other researchers. A data-sharing plan may be developed following completion of the study and analysis of the study results.
Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eplerenone